Immunai logo

Immunai

Mapping the Immune System with AI to Improve Health

174 employees · est. 2019 · New York, United States

VS
Parallel Bio logo

Parallel Bio

Using the immune system to cure disease.

27 employees · est. 2021 · Watertown, United States

Immunai is the older company (2019 vs 2021); Immunai is the larger of the two.

Side-by-Side Comparison

Immunai Parallel Bio
Founded
2019 older 2021
Headquarters
New York, United States Watertown, United States
Employees
174 larger 27
Industry
Biotechnology, Pharmaceutical Biotechnology, Health and Wellness, Life Sciences
Funding Stage
Series B Series A
Total Funding
$300.50M $25.43M
Funding Rounds
5 4
Services
Target Discovery, Preclinical Evaluation, Clinical Trial Optimization, Data Generation, Data Augmentation, Compute and Validate Therapeutic Insights, Recommendation Engine Human-first Drug Discovery, Precision Medicine Solutions, Foundation Model Development, Biological Atlas Creation
Target Customers
biopharmaceutical companies, research institutions, pharma companies Pharmaceutical Companies, Biotech Firms, Research Institutions, Healthcare Providers
Taxonomy
Immune System Mapping, Single-cell Genomics, Biotech, Therapeutic Discoveries, Drug Development, Patient Outcomes, Biomarker Discovery, High-resolution Profiling, Immune Profiling, Cellular Response Analysis, Cancer Research, Genomic Technologies, High-dimensional Statistics, Single-cell Biology Immune System Organoids, Drug Discovery, Immunotherapy Development, Computational Biology, Biotechnology Innovation, Human Health Insights, Disease Modeling, Organoid Technology, Therapeutic Discovery, Immune System Research, Personalized Medicine, Clinical Insights, Health Technology, Precision Medicine
Website
immunai.com parallel.bio
Immunai logo

About Immunai

Immunai, founded in 2019, is a United States-based startup that is revolutionizing the Biotechnology and Pharmaceutical industries with its innovative approach. The company's slogan, "Mapping the Immune System with AI to Improve Health," reflects its mission to map and decode the immune system using...

Parallel Bio logo

About Parallel Bio

Parallel Bio is a promising startup founded in 2021, aiming to revolutionize the field of drug discovery with its innovative technology. The company has developed a groundbreaking platform described as a human 'immune system in a dish', which holds the potential to significantly improve the efficien...

We will tell you when either one moves

BounceWatch watches Immunai and Parallel Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Immunai and Parallel Bio — by email.

Frequently Asked Questions

Immunai — Mapping the Immune System with AI to Improve Health. Parallel Bio — Using the immune system to cure disease.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Immunai has raised $300.50M while Parallel Bio has raised $25.43M.
Immunai and Parallel Bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Immunai with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Immunai on 3 Aug 2026, and Parallel Bio on 4 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy